PenkeTrading Posted - 3 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Sight Sciences Inc. Is that bullish or bearish? $SGHT #RsiOversold #NASDAQ

d_risk Posted - 2 weeks ago

$SGHT - 10Q - Updated Risk Factors New risk factor: Challenges in securing third-party coverage for Surgical Glaucoma and Dry Eye products could impact operations. No substantial changes to other risks. https://d-risk.ai/SGHT/10-Q/2024-11-07

swingingtech Posted - 2 weeks ago

$CMPS, $SGHT, $PACS https://wallstreetwaves.com/must-watch-health-care-stocks-to-buy-before-november-ends/

G101SPM Posted - 2 weeks ago

$SGHT $4.93 bid. DAC (dollar average cost) $6.08 (8.21.24) CHANGE EXIT TO $7.00 FROM $11.50. UPDATE: Lake Street analyst Frank Takkinen commented, "With finalized outpatient prospective payment systems, CMS did not confirm device-intensive reimbursement for canaloplasty (66174) in the ASC setting. Instead, ASC reimbursement unchanged vs. 2024 at ~$2,094/procedure (+2% Y/Y). Device-intensive was proposed at $2,644 (+29% Y/Y). The policy is set to go into effect in January 2025... Unfortunately, this is a competitive space and glaucoma surgeons have multiple effective options. As a result, we think numbers could be at risk. As we await more company guidance (earnings Nov 7), we are leaving our numbers unchanged. While we think the downside is relatively limited given the valuation, upside is likely capped until further clarity. Thus, we are downgrading to a Hold rating and lowering our PT to $5."

insiderbuyingselling Posted - 1 month ago

$SGHT new insider selling: 42318 shares. http://insiderbuyingselling.com/?t=SGHT

insiderbuyingselling Posted - 1 month ago

$SGHT new insider selling: 41704 shares. http://insiderbuyingselling.com/?t=SGHT

themacromindset Posted - 1 month ago

$SGHT Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

insiderbuyingselling Posted - 1 month ago

$SGHT new insider selling: 3167 shares. http://insiderbuyingselling.com/?t=SGHT

insiderbuyingselling Posted - 1 month ago

$SGHT new insider selling: 12727 shares. http://insiderbuyingselling.com/?t=SGHT

G101SPM Posted - 1 month ago

$SGHT $5.92 bid. DAC $6.08 (8.21.24). EXIT $11.50 RETAIN POSITION. BRIEF: On October 3, 2024, four Medicare Administrative Contractors (MACs, each published final local coverage determinations and related final local coverage articles regarding Micro-Invasive Glaucoma Surgery ('MIGS'). ^^ ^^^ Coverage for canaloplasty in combination with trabeculotomy ab interno procedures and goniotomy procedures will continue in the states covered by these MACs; effective November 17, 2024.

G101SPM Posted - 09/27/24

$SGHT $6.57 last bid. DAC $6.08 (8.21.24. EXIT $11.5-. BRIEF: On 9.26.24 26, Noridian Healthcare Solutions, the Medicare Administrative Contractor ("MAC") for sixteen (16) states and U.S. territories, published a final local coverage determination and related final local coverage article (collectively, the "Final LCD") regarding Micro-Invasive Glaucoma Surgery ("MIGS"). The Final LCD, which is substantially similar to the proposed LCD published by Noridian in May 2024, confirms Medicare coverage for phacoemulsification / intraocular lens placement procedures performed with a single MIGS procedure. The Company plans to continue to engage with each MAC, the Centers for Medicare and Medicaid Services, and the clinical societies in continued support of procedures performed with OMNI and SION.

G101SPM Posted - 3 months ago

$SGHT $6.12 bid. Hold long position UPDATE FROM THE OTHER SIDE: Sight Sciences: Underappreciated reimbursement visibility, returning to growth, shares still cheap; initiating with Buy rating and $10 PT -- Lake Street . Analyst Frank Takkinen commented, "We believe investors are underappreciating Sight's ability to reaccelerate growth from -4% Y/Y in 1H24 toward historical rates (2020-2023 CAGR: 43%). We remain conservative, but, assuming policies are finalized in their current form, we think 13% consensus growth in 2025 will be too low. Despite shares rebounding >4x from 2023 lows, we think there is still a disconnect vs. comps and expect policy finalization, execution, and upside to numbers to close the remaining valuation gap. Shares trade at 2.4x '25 EV/Rev vs. pure-play ophthalmology at 6.6x. The balance sheet is solid with $118M of cash at Q2'24 end (Q2'24 burn: $9M). We think proposals are relatively derisked near-term catalysts."

G101SPM Posted - 3 months ago

$SGHT $6.08 ask. BUY/NEW LONG POSITION carries SPM 87.74 tag to EXUT $11.50 in midterm.

lawson Posted - 3 months ago

$SGHT IPO @ $24 if I recall correctly. Tanked all the way to a ~buck and now trades 75% below the IPO price. CEO Paul Badawi, perhaps you could resign and let a better performing CEO take over?

lawson Posted - 3 months ago

$SGHT CEO Paul Badawi has IMO seemingly shit the bed. Flat performance and huge cash burn. The PPS should tell him what wall street thinks of his performance.

Sc_McDuck Posted - 3 months ago

$SGHT Poop.

Stock_Titan Posted - 3 months ago

$SGHT Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance https://www.stocktitan.net/news/SGHT/sight-sciences-reports-second-quarter-2024-financial-results-and-o3fnnty9w41m.html

NVDAMillionaire Posted - 3 months ago

$SGHT Sight Sciences, Inc. (NASDAQ:SGHT): Transforming Ophthalmic Care with Innovative Surgical and Dry Eye Solutions http://beyondspx.com/2024/07/31/sight-sciences-inc-nasdaqsght-transforming-ophthalmic-care-with-innovative-surgical-and-dry-eye-solutions/

lawson Posted - 07/31/24

$SGHT Earning to be announced tomorrow. Hoping for more good news.

Doozio Posted - 07/25/24

Thursday 🐑 low unless yo $blnd. A 🧠⏰ FRYday is in $sght YO $hear

Doozio Posted - 3 months ago

Chop chop huckleberries n don’t $BLNK or yo maybe $blnd with out $sght during 🧠⏰♾️

Doozio Posted - 3 months ago

Bahhht whut happens wen da 🐑 isn’t $blnd no moar n has $sght goin $yrd in 🧠⏰♾️?

StockBoyAri Posted - 3 months ago

$SGHT this moves quick it looks like. I like $9+ here just my opinion.

Stock_Titan Posted - 4 months ago

$SGHT Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 https://www.stocktitan.net/news/SGHT/sight-sciences-to-report-second-quarter-financial-results-on-august-abjk2rd70t3s.html

KCclean Posted - 4 months ago

$SGHT yes

Doozio Posted - 4 months ago

Even da $blnd bums are starting TTWO get their $sght in 🧠⏰♾️

StockBoyAri Posted - 4 months ago

$SGHT $9+ here

lawson Posted - 4 months ago

$SGHT great week

KCclean Posted - 4 months ago

$SGHT yes

Thestocktraderhubzee Posted - 4 months ago

WATCHLIST JUL 11 2024. $TAP Citigroup Maintains Sell on Molson Coors Beverage, Lowers Price Target to $47 $KRUS Citigroup Maintains Neutral on Kura Sushi USA, Lowers Price Target to $68 $SGHT Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6.5 $MDT Citigroup Maintains Neutral on Medtronic, Lowers Price Target to $85 $IART Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $30